At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
Commentary|Articles|November 17, 2014
Rindopepimut for Recurrent Glioblastoma
Author(s)David Reardon, MD
David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, president, Society for Neuro-Oncology, describes the mechanism of action of rindopepimut for recurrent glioblastoma.
Advertisement
Clinical Pearls
David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, president, Society for Neuro-Oncology, describes the mechanism of action of rindopepimut for recurrent glioblastoma.
- Rindopepimut (CDX-110) is a synthetic peptide vaccine designed to target the mutant epidermal growth factor receptor variant III.
- This mutation drives tumor growth and is present in approximately 30% of glioblastoma tumors.
- Rindopepimut sensitizes the immune system against this mutant receptor on glioblastoma tumor cells.
<<<
Advertisement
Related to this article
FYB206 is being reviewed as a pembrolizumab biosimilar after meeting pharmacokinetic equivalence; no additional efficacy trial is required.
Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
Real-World Data for Darolutamide vs Abiraterone Triplet Therapy in mHSPC
4
Sofetabart Mipitecan Elicits Responses Across FRα Levels in Ovarian Cancer
5